The Pharmacy Times® Oncology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
Oral Relugolix Shows Similar Rate of Castration Resistance-free Survival to IV Leuprolide Acetate in Advanced Prostate Cancer
The results of an additional secondary endpoint from the phase 3 HERO study evaluating oral relugolix in men with advanced prostate cancer showed that relugolix had a similar rate of castration resistance-free survival compared to intravenous leuprolide acetate in men with metastatic disease through 48 weeks.
Using a 3D model, investigators found a soy-based compound was effective in treating bone cancer.
At ESMO 2020, researchers discussed some long-awaited data regarding postoperative radiotherapy used in patients with non-small cell lung cancer following complete resection and after (neo) adjuvant chemotherapy.
New drug application been submitted for TLX591-CDx (illumet), a radiopharmaceutical product that targets prostate-specific membrane antigen for the imaging of prostate cancer.
No Survival Improvement From Radical Hysterectomy in Patients With Cervical Cancer, Intraoperative Detection of Positive Lymph Node Involvement
Among patients with cervical cancer, there was no significant difference found between the risk of recurrence, local recurrence, or death among individuals who either completed or abandoned a radical uterine procedure following the intraoperative detection of a positive pelvic lymph node.
The FDA has granted fast track designation to DKN-01 for the treatment of patients with gastric and gastroesophageal junction adenocarcinoma whose tumors have high DKK1 expression.
Study: Early Evaluation of Nutritional Status Needed to Provide Support, Decrease Risk of Malnutrition in Cancer Patients
Study shows that upon hospital admission for cancer, many patients already have a high prevalence of malnutrition per Global Leadership Initiative on Malnutrition criteria.
The results from a cohort of patients with rare sarcomas in the phase 2 study, presented by professor Jean-Yves Blay, MD, investigated the efficacy and safety of single agent pembrolizumab in rare cancers.
A new study showed that nivolumab was effective in patients with pathogenic exonuclease domain POLE mutated mismatch repair.
Study: Pralsentinib May Be an Effective Treatment for RET Mutation-Positive Medullary Thyroid Cancer
The effects of pralsentinib were especially pronounced in treatment-naïve patients with medullary thyroid cancer.
Outcome Indicators Identified for Nivolumab Treatment of Patients With Metastatic Clear Cell Renal Cell Carcinoma
The predictive value provided by T effector and angiogenesis signatures were found to be augmented by Kidney Immune Classification of tumor microenvironments.
Although immune checkpoint inhibitors are not yet approved for first-line therapy in these populations, the new research could lead to a new standard of care.